MXPA03009571A - Metodo para tratar la gota y unir el acido urico. - Google Patents

Metodo para tratar la gota y unir el acido urico.

Info

Publication number
MXPA03009571A
MXPA03009571A MXPA03009571A MXPA03009571A MXPA03009571A MX PA03009571 A MXPA03009571 A MX PA03009571A MX PA03009571 A MXPA03009571 A MX PA03009571A MX PA03009571 A MXPA03009571 A MX PA03009571A MX PA03009571 A MXPA03009571 A MX PA03009571A
Authority
MX
Mexico
Prior art keywords
uric acid
polymer
patient
treating gout
binding
Prior art date
Application number
MXPA03009571A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Randall Holmes-Farley
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MXPA03009571A publication Critical patent/MXPA03009571A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dental Preparations (AREA)
  • Adhesives Or Adhesive Processes (AREA)
MXPA03009571A 2001-04-18 2002-04-10 Metodo para tratar la gota y unir el acido urico. MXPA03009571A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28444501P 2001-04-18 2001-04-18
US30556701P 2001-07-13 2001-07-13
PCT/US2002/011492 WO2002085381A1 (en) 2001-04-18 2002-04-10 Method for treating gout and binding uric acid

Publications (1)

Publication Number Publication Date
MXPA03009571A true MXPA03009571A (es) 2004-02-12

Family

ID=26962624

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03009571A MXPA03009571A (es) 2001-04-18 2002-04-10 Metodo para tratar la gota y unir el acido urico.

Country Status (9)

Country Link
US (2) US20030039627A1 (enExample)
EP (1) EP1416942B1 (enExample)
JP (1) JP2004528332A (enExample)
AT (1) ATE380553T1 (enExample)
BR (1) BR0209133A (enExample)
CA (1) CA2444347A1 (enExample)
DE (1) DE60224052T2 (enExample)
MX (1) MXPA03009571A (enExample)
WO (1) WO2002085381A1 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US7220406B2 (en) * 2002-10-22 2007-05-22 Genzyme Corporation Method for promoting bone formation
WO2004099288A1 (en) * 2003-05-09 2004-11-18 Carlsberg A/S Polyethyleneimine polymers
US7335795B2 (en) * 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7449605B2 (en) * 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7385012B2 (en) * 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7608674B2 (en) 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7767768B2 (en) * 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
EP1830832A1 (en) * 2004-12-30 2007-09-12 Genzyme Corporation Zinc-containing treatments for hyperphosphatemia
CA2607953A1 (en) * 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
WO2007027566A2 (en) * 2005-09-02 2007-03-08 Genzyme Corporation Method for removing phosphate and polymer used therefore
CA2622693C (en) 2005-09-15 2015-05-05 Genzyme Corporation Sachet formulation for amine polymers
JP2009514966A (ja) * 2005-11-08 2009-04-09 ジェンザイム・コーポレーション 高リン血症のためのマグネシウム含有重合体
WO2007130463A2 (en) * 2006-05-05 2007-11-15 Genzyme Corporation Amine condensation polymers as phosphate sequestrants
WO2008005217A2 (en) * 2006-07-05 2008-01-10 Genzyme Corporation Iron(ii)-containing treatments for hyperphosphatemia
WO2008011047A2 (en) * 2006-07-18 2008-01-24 Genzyme Corporation Amine dendrimers
EP2066293A2 (en) 2006-09-29 2009-06-10 Genzyme Corporation Amide dendrimer compositions
US20090124623A1 (en) * 2006-11-13 2009-05-14 Christopher Lademacher Methods for preserving and/or increasing renal function using xanthine oxidoreductase inhibitors
EP2101761A4 (en) * 2006-11-13 2010-01-27 Takeda Pharmaceuticals North A METHODS FOR PRESERVING RENAL FUNCTION USING XANTHINE OXYDOREDUCTASE INHIBITORS
US8163799B2 (en) 2006-12-14 2012-04-24 Genzyme Corporation Amido-amine polymer compositions
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
EP2114376A1 (en) * 2007-02-23 2009-11-11 Genzyme Corporation Amine polymer compositions
JP2010520285A (ja) * 2007-03-08 2010-06-10 ゲンズイメ コーポレーション スルホンポリマー組成物
EP2152277A1 (en) * 2007-04-27 2010-02-17 Genzyme Corporation Amido-amine dendrimer compositions
EP2217215A1 (en) * 2007-12-14 2010-08-18 Genzyme Corporation Coated pharmaceutical compositions
US20110142952A1 (en) * 2008-06-20 2011-06-16 Harris David J Pharmaceutical Compositions
US20100311756A1 (en) * 2009-01-22 2010-12-09 Takeda Pharmaceuticals North America, Inc. Methods for delaying the progression of at least one of cardiac hypertrophy, cardiac remodeling or left ventricular function or the onset of heart failure in subjects in need of treatment thereof
ES2532210T3 (es) 2010-09-10 2015-03-25 Takeda Pharmaceuticals U.S.A., Inc. Métodos para el tratamiento concomitante de teofilina y febuxostat
LT3003327T (lt) 2013-06-05 2017-12-27 Tricida Inc. Protonus surišantys polimerai, skirti geriamajam vartojimui
CN113855703B (zh) 2014-12-10 2025-11-25 特里赛达公司 用于口服施用的质子结合聚合物
WO2017193024A1 (en) 2016-05-06 2017-11-09 Tricida, Inc. Hcl-binding compositions for and method of treating acid-base disorders
JP6792640B2 (ja) 2016-12-28 2020-11-25 富士フイルム株式会社 窒素原子含有ポリマー又はその塩の乳化液、その製造方法、及び粒子の製造方法
EP3698799B1 (en) 2017-10-16 2022-01-26 FUJIFILM Corporation Hyperphosphatemia treatment agent
AU2018360867B2 (en) 2017-11-03 2024-12-12 Tricida, Inc. Compositions for and method of treating acid-base disorders
ES2980624T3 (es) * 2021-08-24 2024-10-02 Waterstone Pharmaceuticals Wuhan Co Ltd Polímeros, composiciones y métodos para tratar hiperuricemia
WO2023023938A1 (en) * 2021-08-24 2023-03-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Polymers, compositions and methods for treating hyperuricemia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271191A (en) * 1979-12-19 1981-06-02 Pierre Fabre S.A. Method of treating hyperuricemia and gout
DE3727082A1 (de) * 1987-08-14 1989-02-23 Goedecke Ag Pharmazeutische zubereitungen zur behandlung der urolithiasis
CN1238789A (zh) * 1996-10-23 1999-12-15 陶氏化学公司 用于降低饮食中磷酸根或草酸根吸收的水溶性聚合物
US5985938A (en) * 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
WO2002085380A1 (en) * 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid

Also Published As

Publication number Publication date
EP1416942B1 (en) 2007-12-12
WO2002085381A1 (en) 2002-10-31
EP1416942A1 (en) 2004-05-12
BR0209133A (pt) 2004-06-15
US20030039627A1 (en) 2003-02-27
DE60224052D1 (de) 2008-01-24
DE60224052T2 (de) 2008-11-06
US20080112918A1 (en) 2008-05-15
ATE380553T1 (de) 2007-12-15
JP2004528332A (ja) 2004-09-16
CA2444347A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
ATE380553T1 (de) Aminpolymere zur behandlung von gicht und zur senkung des harnsäuregehaltes
CY1119486T1 (el) Χρηση πολυμερους αμινης για μειωση της γλυκοζης στον ορο
CA2349620A1 (en) Use of aliphatic polyamines for reducing oxalate
MY125874A (en) Use of polyallylamine polymers for the manufacture of a medicament for treating hypercholesterolemia
BR0209124A (pt) Método para tratar uma sìndrome x ou inibir o inìcio dos sintomas da sìndrome x e uso de uma quantidade terapeuticamente efetiva de um sal de pelo menos um polìmero de amina alifática
DK1385898T3 (da) Farmaceutisk sammensætning omfattende poly(alkylenoxider) med reducerede mængder af myresyreforbindelser
HUP0004279A2 (hu) Eljárás hiperkoleszterinémia kezelésére helyettesített poli(diallil-amin)nal
ATE486613T1 (de) Mit nucleinsäure complexierte block-copolymere
TW200621810A (en) A transfer agent for use in the controlled radical polymerisation in solution of acrylic acid
DE60315949D1 (de) Polymerkonjugate
DK0804252T3 (da) Monoamin-, diamid-, thiol-holdige metalchelateringsmidler
IL142419A0 (en) Alkylated crosslinked polymers, method for their preparation and pharmaceutical compositions containing same
WO2002080939A3 (en) Ionene polymers and their use as antimicrobial agents
NZ331934A (en) Polyvalent polymers comprising one or more fucoside monomers for the treatment of rotaviral infections
JP2004526778A5 (enExample)
CA2508282A1 (en) Compositions comprising n-isopropylacrylamide and methods for inhibiting protein adsorption on surfaces
PL374433A1 (en) Method for binding particulate, water-absorbing, acid group-containing polymers to a base material
HOLMES-FARLEY et al. Design and characterization of sevelamer hydrochloride: a novel phosphate-binding pharmaceutical
WO2007056405A8 (en) Magnesium-containing polymers for the treatment of hyperphosphatemia
EP1923064A3 (en) Use of amine polymer for lowering serum glucose
MY131690A (en) 6-[triazolyl[3-(trifluoromethyl) phenyl]methyl]-2- quinolinones and -quinolinethiones
WO2004047779A3 (en) Polymers containing quaternary ammonium salts
WO2002018389A3 (de) Thienopyrimidine
PL355209A1 (en) Use of copolymers derived from polyamides as gelling agents for compounds with low polarity
AU2002220943A1 (en) Pharmaceutical composition for treating obesity